Alitair Announces Issuance of Third Patent for its Drug Delivery Platform
Alitair Pharmaceuticals, Inc. recently announced the issuance of US Patent No. 8,617,602 from theUSPTO for its ion exchange resin drug delivery technology, REA.
“Our propriety ion exchange resin delivery platform can be utilized across a range of therapeutic classes and with many different molecules,” said Alitair President and CEO, William W. Howard, PhD. “The REA platform technology allows us to improve upon currently available therapies and create new solid-oral formulations with less-frequent dosing schedules, both of which have been shown to improve patient adherence.”
“Being awarded this third patent is an important milestone in our product development strategy and the growth of Alitair,” continued Howard. “We will likely use this technology to provide protection for our orphan drug candidates, both of which can be formulated with our REA technology. This would extend the lifespan of our orphan candidates from 7 years to 20, further enhancing their value. We are also actively seeking funding and development partners to build on the momentum we’ve created and advance our product development programs.”
Alitair Pharmaceuticals, Inc. develops medicines for the treatment of respiratory illnesses. Alitair has out-licensed two prescription cough candidates that use its proprietary ion-exchange resin technology (REA). The company has two orphan drug candidates under development. For more information, visit www.alitair.com.
Total Page Views: 1006
